application): All cancer-related protocols involving a UNMC faculty member or a UNMC Eppley Cancer Center member require review by the Scientific Review Committee. The mission of the Scientific Review Committee is complementary to that of the institutional Review Board (IRB). It does not duplicate or overlap the responsibilities of the IRB, which focuses on the protection of human subjects. The IRB will not issue a full approval for any cancerrelated study involving human subjects without first receiving notice of full approval from the Scientific Review Committee which attests that all scientific requirements for the study have been met. The Scientific Review Committee focuses on the scientific merit, prioritization, and progress of the research. The specific objective of the Scientific Review Committee include: ? Review scientific merit of cancer-related research involving human subjects at the UNMC Eppley Cancer Center. ? Foster development of innovative, collaborative, and scientifically sound studies which focus on the prevention, detection, diagnosis, and treatment of cancer including long-term follow-up and supportive care. ? Aid investigators in the establishment of the prioritization of studies and assure optimal allocation of the Cancer Center clinical and community resources. ? Assist investigators in the development and conduct of clinical cancer studies in conjunction with the Clinical Trials Office. ? Monitor progress of protocols relative to study objectives. ? Monitor accrual, data collection, and safety in conjunction with the Data Safety and Monitoring Committee and the Audit Committee. ? Provide a standard protocol format for submission and review.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA036727-22
Application #
7287327
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2006-08-01
Budget End
2007-07-31
Support Year
22
Fiscal Year
2006
Total Cost
$23,087
Indirect Cost
Name
University of Nebraska Medical Center
Department
Type
DUNS #
168559177
City
Omaha
State
NE
Country
United States
Zip Code
68198
Chhonker, Yashpal S; Sleightholm, Richard L; Li, Jing et al. (2018) Simultaneous quantitation of hydroxychloroquine and its metabolites in mouse blood and tissues using LC-ESI-MS/MS: An application for pharmacokinetic studies. J Chromatogr B Analyt Technol Biomed Life Sci 1072:320-327
Lopez, Wilfredo; Page, Alexis M; Carlson, Darby J et al. (2018) Analysis of immune-related genes during Nora virus infection of Drosophila melanogaster using next generation sequencing. AIMS Microbiol 4:123-139
Iseka, Fany M; Goetz, Benjamin T; Mushtaq, Insha et al. (2018) Role of the EHD Family of Endocytic Recycling Regulators for TCR Recycling and T Cell Function. J Immunol 200:483-499
Barger, Carter J; Zhang, Wa; Sharma, Ashok et al. (2018) Expression of the POTE gene family in human ovarian cancer. Sci Rep 8:17136
Huang, Yunlong; Li, Yuju; Zhang, Hainan et al. (2018) Zika virus propagation and release in human fetal astrocytes can be suppressed by neutral sphingomyelinase-2 inhibitor GW4869. Cell Discov 4:19
Kumar, Vinod; Kumar, Virender; Chaudhary, Amit Kumar et al. (2018) Impact of miRNA-mRNA Profiling and Their Correlation on Medulloblastoma Tumorigenesis. Mol Ther Nucleic Acids 12:490-503
Fan, Wei; Zhang, Wenting; Alshehri, Sameer et al. (2018) Increasing time on target: utilization of inhibitors of cysteine cathepsins to enhance the tumor retention of receptor-targeted agents. Chem Commun (Camb) 54:11268-11271
Baranovskiy, Andrey G; Siebler, Hollie M; Pavlov, Youri I et al. (2018) Iron-Sulfur Clusters in DNA Polymerases and Primases of Eukaryotes. Methods Enzymol 599:1-20
Ouellette, Scot P; Messerli, Parker R; Wood, Nicholas A et al. (2018) Characterization of Chlamydial Rho and the Role of Rho-Mediated Transcriptional Polarity during Interferon Gamma-Mediated Tryptophan Limitation. Infect Immun 86:
Robb, Caroline M; Kour, Smit; Contreras, Jacob I et al. (2018) Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy. Oncotarget 9:5216-5232

Showing the most recent 10 out of 1372 publications